Abstract
African-American men and black men throughout the world have a higher rate of prostate cancer than other ethnic groups. They also are most likely to present at a younger age with more advanced disease and have historically had a poorer prognosis. Whether this observed difference is due to behavior, lack of access, environmental factors or genetics is hotly debated. Whatever the cause or causes, there is growing concensus that targeting screening to this high-risk group is justified. Focused education about risk and screening in black men can be effective and demonstration screening programs in African-American community settings have been successful.
There is much debate about the proper normal values of PSA to be used in screening high risk black men. Some have argued for a very low normal range such as ≤2.0 ng/ml to improve sensitivity for detection of curable disease. Others, recognizing the balance between sensitivity (cancer detection) and specificity (avoiding unnecessary prostate biopsies), have proposed age-adjusted PSA ranges.
Until randomized or prospective screening trials are completed, it seems reasonable to encourage black men to start screening at age 40 using a PSA threshold of ≤2.0 to 2.5 ng/ml to prompt further evaluation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
The opinion and assertions contained herein are the private views of the authors and are not be construed as reflecting the views of the US Army of the Department of Defense.
Rights and permissions
About this article
Cite this article
Moul, J. Targeted screening for prostate cancer in African-American men. Prostate Cancer Prostatic Dis 3, 248–255 (2000). https://doi.org/10.1038/sj.pcan.4500472
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500472